Despite advancements in tumor immunotherapy, inconsistent therapeutic effects and
barriers impacting clinical outcomes highlight the need for a better understanding of the …

Despite recent clinical advances in immunotherapy, a fraction of cancer patients fails to
respond to these interventions. Evidence from preclinical mouse models as well as clinical …

Cancer immunotherapy harnesses the ability of the immune system to recognize and
eliminate cancer. The potent ability of dendritic cells (DCs) to initiate and regulate adaptive …

For more than a century, scientists have tried to exploit the anti-tumoral potential of the
immune system to treat cancer. However, clinical success was traditionally limited …

Recent advances in cancer immunotherapy, particularly immune checkpoint blockade
therapy have dramatically changed the therapeutic strategy against advanced malignancies …

Although the ever-increasing number of cancer patients pose substantial challenges
worldwide, finding a treatment with the highest response rate and the lowest number of side …

The importance of the immune system in the response against cancer has always been a
subject of intense investigation. The advent of immune checkpoint inhibitors has transformed …

Despite continual hints from preclinical and clinical research of its relevance, cancer
immunology existed for many years at the periphery of cancer therapeutics. It is now the …

Harnessing the broad immunostimulatory capabilities of chemotherapy in combination with
immune checkpoint inhibitors has improved immunotherapy outcomes in patients with …

The advances in immunotherapies in the last decades have brought new hope in the battle
against cancer (Wang et al., 2019; Morad et al., 2021). These therapies include immune …